Replies to post #4506 on Safeplus International Holdings Ltd. (ACAI)

[krays]

I agree, and speaking of patents, the patent I just posted about relates to the CSS device itself and addresses acute care for an arrested heart. Another patent application that I posted about recently (currently under review by USPTO) relates to therapeutic care for an enlarged heart. My thoughts are that the second application may provide a quicker strategy to bring this device to market as it may be much easier to initiate clinical trials and obtain consent from a living patient with an enlarged heart vs. a basically dead patient in cardiac arrest.

I would vote my significant number of shares in favor of the increase but apparently they are not eligible.
Regards,

[sunspotter]

"If anyone believes in BIPH and is upset about the dilution, then buy more shares, cost averging down. That is, of course, if you want to put more money into the stock. At 1.5 cents or less, I'm sure someone could add enough shares to cost average down and take a nice position for the future."

If past form is anything to go by, then there are a number of Biophan "longs" who would be delighted to sell you some of their shares. Just don't expect them to acknowledge their philanthropy publically - in the past when they've sold their shares (also known as "rotating out of their core holdings") they've continued to encourage others to buy.

Kinda selfless guys that are typical of the BIPH long, I guess.

"Trying to figure another way to turn things around will increase the cash burn, as well as encourage more financing, spiraling BIPH into near certain death. This type of strategy is more risky than dilution."

Orwell's Winston Smith would be familiar with this logic:

"WAR IS PEACE"
"FREEDOM IS SLAVERY"
"IGNORANCE IS STRENGTH"
"NON-DILUTION IS WORSE THAN MEGADILUTION"

Truth is, Biophan doesn't need any extra shares to out-license the Myotech CSS device, and nobody looking to acquire rights to that technology wants Biophan shares. They just want a financially stable partner they can trust.

Partners that have the potential to issue nearly three times their entire float overnight to whatever toxic finance crew offers them enough money to pay salaries for another two or three years don't really fall into that category, I'm afraid.

As for Biophan needing the shares to "pay" for another acquisition, frankly that shouldn't be considered in their business model (if they actually have one). They need to demonstrate they can deliver on the technology to which they already own rights.

What Biophan needs to do is formulate a plan for developing the Myotech CSS device via human studies, discuss it with FDA, communicate to shareholders with timed milestones, and just "get her done".

It's not rocket science and it doesn't require MegaDilution.

Just honest capable management.

Question is, does Biophan have that, or is it going to continue impoverishing shareholders while enriching its "management" and their known associates, encouraged by some posters with frankly incomprehensible private agendas?